Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Over-expression of Epidermal Growth Factor Receptor (EGFR) on cells occurs in all aggressive
cancers of epithelial origin. Existing tests for monitoring EGFR expression are invasive and
not reliable. There needs to be a better way to measure EGFR expression in cancerous tumors
to better tailor cancer treatments.
This clinical trial aims to demonstrate the feasibility of imaging cancers that express EGFR
using 89Zr-DFO-nimotuzumab and Positron Emission Tomography (PET)/Computerized Tomography
(CT). By non-invasively imaging the status of EGFR, 89Zr-DFO-nimotuzumab could be used to
assist in the identification of patients who are likely to respond to anti-EGFR treatments,
including nimotuzumab. The hypothesis is that 89Zr-DFO-nimotuzumab will accumulate to tumors
over-expressing EGFR making them visible when imaged with PET/CT. This hypothesis will be
tested in this study, along with the optimal imaging time and diagnostic ability.